BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hálfdánarson ÓÖ, Pottegård A, Björnsson ES, Lund SH, Ogmundsdottir MH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton-pump inhibitors among adults: a nationwide drug-utilization study. Therap Adv Gastroenterol 2018;11:1756284818777943. [PMID: 29872455 DOI: 10.1177/1756284818777943] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Helgadottir H, Bjornsson ES. Problems Associated with Deprescribing of Proton Pump Inhibitors. Int J Mol Sci 2019;20:E5469. [PMID: 31684070 DOI: 10.3390/ijms20215469] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hálfdánarson ÓÖ, Pottegård A, Lund SH, Ogmundsdottir MH, Ogmundsdottir HM, Zoega H. Use of proton pump inhibitors and mortality among Icelandic patients with prostate cancer. Basic Clin Pharmacol Toxicol 2020;126:484-91. [PMID: 31872571 DOI: 10.1111/bcpt.13379] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Bustillos H, Leer K, Kitten A, Reveles KR. A cross-sectional study of national outpatient gastric acid suppressant prescribing in the United States between 2009 and 2015. PLoS One 2018;13:e0208461. [PMID: 30500865 DOI: 10.1371/journal.pone.0208461] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Ágústsson AS, Ingason AB, Rumba E, Pálsson D, Reynisson IE, Hreinsson JP, Björnsson ES. Causes of gastrointestinal bleeding in oral anticoagulant users compared to non-users in a population-based study. Scand J Gastroenterol 2021;:1-7. [PMID: 34749581 DOI: 10.1080/00365521.2021.1998600] [Reference Citation Analysis]
5 Bruin MM, Deijkers RLM, Bazuin R, Elzakker EPM, Pijls BG. Proton-pump inhibitors are associated with increased risk of prosthetic joint infection in patients with total hip arthroplasty: a case-cohort study. Acta Orthop 2021;92:431-5. [PMID: 33977828 DOI: 10.1080/17453674.2021.1920687] [Reference Citation Analysis]
6 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
7 Schubert ML. Proton pump inhibitors: placing putative adverse effects in proper perspective. Current Opinion in Gastroenterology 2019;35:509-16. [DOI: 10.1097/mog.0000000000000580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
8 Castellana M, Castellana C, Giovanella L, Trimboli P. Prevalence of gastrointestinal disorders having an impact on tablet levothyroxine absorption: should this formulation still be considered as the first-line therapy? Endocrine 2020;67:281-90. [PMID: 31953721 DOI: 10.1007/s12020-019-02185-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
9 Rückert-Eheberg IM, Nolde M, Ahn N, Tauscher M, Gerlach R, Güntner F, Günter A, Meisinger C, Linseisen J, Amann U, Baumeister SE. Who gets prescriptions for proton pump inhibitors and why? A drug-utilization study with claims data in Bavaria, Germany, 2010-2018. Eur J Clin Pharmacol 2021. [PMID: 34877614 DOI: 10.1007/s00228-021-03257-z] [Reference Citation Analysis]
10 Rosenberg V, Tzadok R, Chodick G, Kariv R. Proton pump inhibitors long term use-trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiol Drug Saf 2021;30:1576-87. [PMID: 34453456 DOI: 10.1002/pds.5352] [Reference Citation Analysis]
11 Cetin H, Wurm R, Reichardt B, Tomschik M, Silvaieh S, Parvizi T, König T, Erber A, Schernhammer E, Stamm T, Stögmann E. Increased risk of death associated with the use of proton-pump inhibitors in patients with dementia and controls - a pharmacoepidemiological claims data analysis. Eur J Neurol 2020;27:1422-8. [PMID: 32281706 DOI: 10.1111/ene.14252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
13 Blanc F, Waechter C, Vogel T, Schorr B, Demuynck C, Hunyadi CM, Meyer M, Mutelica D, Bougaa N, Fafi-Kremer S, Calabrese L, Schmitt E, Imperiale D, Jehl C, Boussuge A, Suna C, Weill F, Matzinger A, Muller C, Karcher P, Kaltenbach G, Sauleau E. Therapeutic prevention of COVID-19 in elderly: a case-control study. Geroscience 2021. [PMID: 34273049 DOI: 10.1007/s11357-021-00397-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Patil T, Murphy K, Woodard L, Lebrecht M. Proton Pump Inhibitor Utilization in Veteran Patients on Combined Antithrombotic Therapy and Validation of Simplified Bleeding Risk Score. Pharmacotherapy 2020;40:1219-27. [PMID: 33073362 DOI: 10.1002/phar.2477] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Brusselaers N, Sadr-Azodi O, Engstrand L. Proton pump inhibitors and the risk of pancreatic cancer. J Gastroenterol 2021;56:295-6. [PMID: 33527212 DOI: 10.1007/s00535-021-01761-8] [Reference Citation Analysis]
16 Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol 2020;55:453-61. [PMID: 31811561 DOI: 10.1007/s00535-019-01652-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
17 Paškevičiūtė M, Petrikaitė V. Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures. Cancer Manag Res 2019;11:9761-9. [PMID: 31819614 DOI: 10.2147/CMAR.S224097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
18 Nolde M, Ahn N, Dreischulte T, Rückert-Eheberg IM, Güntner F, Günter A, Gerlach R, Tauscher M, Amann U, Linseisen J, Meisinger C, Baumeister SE. The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018). Aliment Pharmacol Ther 2021;54:1033-40. [PMID: 34476821 DOI: 10.1111/apt.16565] [Reference Citation Analysis]
19 Li CM, Zhernakova A, Engstrand L, Wijmenga C, Brusselaers N. Systematic review with meta-analysis: the risks of proton pump inhibitors during pregnancy. Aliment Pharmacol Ther 2020;51:410-20. [DOI: 10.1111/apt.15610] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
20 Hálfdánarson ÓÖ, Fall K, Ogmundsdottir MH, Lund SH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471-8. [DOI: 10.1002/pds.4702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
21 Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, Fang F, Ingre C. No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study. Sci Rep 2020;10:13371. [PMID: 32770128 DOI: 10.1038/s41598-020-70373-8] [Reference Citation Analysis]
22 Puchon E, Goboova M, Vano I, Fazekas T, Javorova-rihova Z, Kuzelova M. Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults. Eur Geriatr Med 2020;11:1051-61. [DOI: 10.1007/s41999-020-00380-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Bruno C, Pearson SA, Daniels B, Buckley NA, Schaffer A, Zoega H. Passing the acid test? Evaluating the impact of national education initiatives to reduce proton pump inhibitor use in Australia. BMJ Qual Saf 2020;29:365-73. [PMID: 31641029 DOI: 10.1136/bmjqs-2019-009897] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
24 Madison AA, Kiecolt-Glaser JK. The gut microbiota and nervous system: Age-defined and age-defying. Semin Cell Dev Biol 2021;116:98-107. [PMID: 33422403 DOI: 10.1016/j.semcdb.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ghebre YT. Proton Pump Inhibitors and Osteoporosis: Is Collagen a Direct Target? Front Endocrinol (Lausanne) 2020;11:473. [PMID: 32793122 DOI: 10.3389/fendo.2020.00473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, Dumarcet N, Zureik M, Dray-Spira R. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol 2020;76:449-57. [PMID: 31838548 DOI: 10.1007/s00228-019-02810-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
27 Matuz M, Benkő R, Engi Z, Schváb K, Doró P, Viola R, Szabó M, Soós G. Use of Proton Pump Inhibitors in Hungary: Mixed-Method Study to Reveal Scale and Characteristics. Front Pharmacol 2020;11:552102. [PMID: 33013389 DOI: 10.3389/fphar.2020.552102] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
28 Muheim L, Signorell A, Markun S, Chmiel C, Neuner-Jehle S, Blozik E, Ursprung P, Rosemann T, Senn O. Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therap Adv Gastroenterol 2021;14:1756284821998928. [PMID: 33948109 DOI: 10.1177/1756284821998928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Current Opinion in Gastroenterology 2018;34:451-7. [DOI: 10.1097/mog.0000000000000471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
30 Sabourin AA, Fisher-Grant KK, Saulles AR, Mohammad RA. Evaluation of a specialty hepatitis C virus telephone pharmacy service. Am J Health Syst Pharm 2021;78:S38-45. [PMID: 33684928 DOI: 10.1093/ajhp/zxaa423] [Reference Citation Analysis]
31 Daniels B, Schaffer A, Buckley NA, Bruno C, Jun M, Pearson SA, Zoega H. The impact of tightened prescribing restrictions on proton pump inhibitor use in Australia: An evaluation using interrupted time series analysis. Pharmacoepidemiol Drug Saf 2021. [PMID: 34894368 DOI: 10.1002/pds.5395] [Reference Citation Analysis]
32 Kanno T, Moayyedi P. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. Curr Gastroenterol Rep 2019;21:65. [PMID: 31807948 DOI: 10.1007/s11894-019-0732-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Maret-Ouda J, Markar SR, Lagergren J. Gastroesophageal Reflux Disease: A Review. JAMA 2020;324:2536-47. [PMID: 33351048 DOI: 10.1001/jama.2020.21360] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
34 Ding DC, Sung FC, Chen W, Wang JH, Lin SZ. Proton pump inhibitors reduce breast cancer risk in gastric ulcer patients: A population-based cohort study. Breast J 2020;26:474-8. [PMID: 31478297 DOI: 10.1111/tbj.13519] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
35 Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. Therap Adv Gastroenterol 2020;13:1756284820913743. [PMID: 32218806 DOI: 10.1177/1756284820913743] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
36 Bhattacharya S, Blau JE, Cochran C, Auh S, Weinstein LS, Jensen RT, Wank S. Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome. Am J Gastroenterol 2021;116:2216-21. [PMID: 34515664 DOI: 10.14309/ajg.0000000000001487] [Reference Citation Analysis]
37 Moayyedi P. How to advise patients on the risk of chronic proton pump inhibitor therapy. Curr Opin Gastroenterol 2020;36:317-22. [PMID: 32487851 DOI: 10.1097/MOG.0000000000000641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]